Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver

Table 1

Patient characteristics, clinical profiles, and immunological outcomes.

Antibody titers; 226.88 ± 164; [IU/mL]	Total	Nonresponders; [<10 IU/mL]	Partial; responders; [10–100 IU/mL]	Responders; [>100 IU/mL]	𝑃 value
Age group 47.48 ± 9.37 [years]
<50	30	3 [10%]	6 [20%]	21 [70%]	0.03
>50	22	8 [36%]	5 [23%]	9 [41%]
Total	52	11 [21%]	11 [21%]	30 [58%]
Gender
Female	15	2 [13%]	2 [13%]	11 [74%]	0.43
Male	37	9 [24%]	8 [22%]	20 [54%]
Total	52	11 [21%]	10 [19%]	31 [60%]
Etiology
Alcohol	27	8 [30%]	7 [26%]	12 [44%]	0.36
Hepatitis C	8	1 [12%]	1 [12%]	6 [76%]
Cryptogenic	13	2 [15%]	2 [15%]	9 [70%]
Others	4	0	0	4 [100%]
Total	52	11 [21%]	10 [19%]	31 [60%]
Child’s class
A	25	2 [8%]	1 [4%]	22 [88%]	<0.0001
B	27	9 [33.3%]	9 [33.3%]	9 [33.3%]
Total	52	11 [21%]	10 [19%]	31 [60%]